文献速递肝病

分子特征区分人肝移植后不同类型排斥反应

Molecular signatures discriminating different types of rejection in human liver transplants.
PubMed 文献 · J Hepatol · 2025-07-14

研究对来自两个前瞻性机构生物样本库的肝活检组织进行批量RNA测序(发现队列71例,汉诺威验证队列58例,巴塞罗那验证队列29例),旨在识别肝移植后慢性抗体介导排斥反应(cAMR)的分子特征。结果显示,cAMR具有独特的转录组谱,富集于纤维化、补体激活和TNFα信号通路,且约40-50%的病例后续发生肝硬化。

要点

  • cAMR具有独特的转录组特征,富集纤维化、补体激活与TNFα信号通路。
  • 57%的cAMR患者肝酶正常或接近正常,仅通过监测性活检发现。
  • cAMR与后续肝硬化相关(40-50%病例),而临床TCMR无此关联。

核心结论

  • 肝移植后cAMR具有独特的转录组谱,以炎症和纤维化通路为特征,与其他实体器官移植中的发现一致,且与移植物衰竭高风险相关。

研究设计与样本

  • 研究筛选了两个前瞻性机构生物样本库中的指征性和监测性肝活检组织,进行了批量RNA测序分析。
  • 发现队列样本量为71例,汉诺威验证队列为58例,巴塞罗那验证队列为29例。

主要发现

  • 在训练队列中,具有供体特异性抗体的肝移植受者中19%存在cAMR。
  • 这些cAMR患者中57%肝酶正常或接近正常,cAMR仅通过监测性活检被检测到。
  • cAMR在40-50%的病例中与后续肝硬化相关,其差异表达基因独特地富集于纤维化、补体激活和TNFα信号通路。
  • 相比之下,临床TCMR与复发性肝硬化无关,其差异表达基因富集于抗原呈递、干扰素信号和T细胞受体信号通路。
  • 亚临床TCMR在分子上几乎与无组织学排斥无法区分,且发现队列与验证队列之间的差异表达基因谱高度一致。

临床怎么用

  • 作者认为,研究结果支持使用监测性移植物活检来检测与纤维化相关的cAMR表型。
  • 作者指出,该分子特征未来可能被研究人员和临床医生用于区分cAMR与其他原因导致的移植物损伤。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The role of antibody-mediated rejection (AMR) after liver transplantation (LT) remains controversial. Chronic AMR (cAMR) is often subclinical and may be missed without surveillance biopsies (svLbx). Transcriptome analyses have previously characterized molecular changes in T cell-mediated rejection (TCMR) after solid organ transplantation. We aimed to identify molecular signatures of cAMR after LT. METHODS: Indication and surveillance biopsies from two prospective institutional biorepositories were screened. We performed bulk RNA sequencing on liver biopsies (discovery cohort: n = 71; Hannover validation cohort: n = 58; Barcelona validation cohort: n = 29). Downstream analyses explored the molecular features of cAMR, clinical TCMR, and subclinical TCMR, compared to no histological rejection. RESULTS: Nineteen percent of LT recipients with donor-specific antibodies had cAMR in the training cohort. Of these patients, 57% had normal/near normal liver enzymes, with cAMR detected only by svLbx. cAMR was associated with subsequent cirrhosis in 40-50% of cases and exhibited differentially expressed genes (DEGs) uniquely enriched in pathways related to fibrogenesis, complement activation, and TNFα signaling. In contrast, clinical TCMR was not associated with recurrent cirrhosis and showed DEGs enriched in antigen presentation, interferon signaling, and T cell receptor signaling. Subclinical TCMR was molecularly almost indistinguishable from no histological rejection. DEG profiles showed a high degree of concordance between the discovery and validation cohorts. CONCLUSIONS: We report a distinct transcriptomic profile of cAMR after LT, characterized by inflammatory and fibrogenic pathways, consistent with findings in other solid organ transplant settings. This molecular identity is associated with a high risk of liver graft failure. IMPACT AND IMPLICATIONS: Chronic antibody-mediated rejection (AMR) is a recognized relevant cause of graft injury and unfavorable patient outcomes after kidney, heart and lung transplantation, but the role of chronic AMR after liver transplantation (LT) is controversial. Therefore, we aimed to characterize rejection phenotypes after LT on a molecular basis, as done in other solid organ transplant settings, to identify unique features of chronic AMR. Our findings identify chronic AMR as a molecularly distinct clinical phenotype of rejection after LT, often presenting with normal liver enzymes (validated in three independent cohorts) and associated with a recurrent cirrhosis rate of 40-50%. Our work supports the use of surveillance graft biopsies for the detection of a fibrosis-associated phenotype of chronic AMR. The molecular signature may be used in the future by researchers and clinicians to discriminate chronic AMR from graft injury of other causes.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Engel B, Alaswad A, Campos-Murguia A, et al. Molecular signatures discriminating different types of rejection in human liver transplants. J Hepatol. 2025. PMID: 40669521. doi:10.1016/j.jhep.2025.06.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。